Welcome to our dedicated page for Clarivate Plc news (Ticker: CLVT), a resource for investors and traders seeking the latest updates and insights on Clarivate Plc stock.
Clarivate Plc (NYSE: CLVT) is described as a leading global provider of transformative intelligence, with news that reflects its activities across Academia & Government, Intellectual Property and Life Sciences & Healthcare. Company announcements frequently highlight new AI-powered tools, analytical reports and customer adoptions that illustrate how Clarivate combines enriched data, analytics and workflow software.
Recent news includes the launch of the Web of Science Research Assistant, a generative AI-powered tool that helps researchers conduct natural-language searches, perform literature reviews and explore visualizations based on more than 120 years of publication and citation data. Clarivate also reports on studies such as the Pulse of the Library report, which surveys thousands of librarians worldwide about AI adoption, open science and budget pressures, and on the annual Highly Cited Researchers list, which recognizes researchers whose work has had broad influence based on Web of Science data.
In Intellectual Property, Clarivate issues updates on solutions like IPfolio and Derwent Patent Monitor, including customer selections by organizations such as Nissan Motor Co., Ltd. and FUJIFILM Holdings Corporation. These stories emphasize how IP management platforms and AI-enabled patent review tools support more efficient IP operations and collaboration between IP and R&D teams.
Life sciences and healthcare news often centers on Clarivate analyses such as the Drugs to Watch report and Companies to Watch reports, which identify emerging therapies and innovative companies using integrated, AI-enhanced datasets. Visitors to this news page can follow Clarivate’s product launches, research reports, customer case studies and investor-related announcements to understand how the company is applying data and AI across its core markets.
Clarivate Plc (NYSE: CLVT) has announced the winners of its 2021 Revenue Cycle Awards, recognizing healthcare organizations for outstanding performance in revenue cycle KPIs. Winners include Liberty Hospital, four Ardent Health Services hospitals, University of Iowa Hospitals & Clinics, and Novant Health. These organizations showcased resilience amid challenges from the COVID-19 pandemic, improving efficiency and patient experience. Key achievements were noted in metrics like collection rates, billing accuracy, and staff engagement. The awards program aims to highlight exemplary revenue cycle management in the healthcare sector.
Clarivate Plc (NYSE:CLVT) announces the launch of a Global Research Report detailing the research landscape in eleven Central European countries. The report highlights a strong growth in research output, with these nations producing approximately 4% of global papers from 2016 to 2020, a doubling since 1990. Notably, Estonia and Latvia exhibit high international collaboration rates, reaching around 70%. The findings suggest that EU accession has positively influenced research funding and output.
Clarivate Plc (NYSE: CLVT) has launched a resource center to support displaced researchers from Ukraine. This initiative includes over 200 ProQuest Books available freely, a program ensuring continued access to the Web of Science for Ukrainian institutions, and the RapidILL interlibrary loan system for academic resources. This follows Clarivate's decision to cease commercial activities in Russia. The resource center aims to enhance knowledge and understanding of Ukraine while providing critical support for research and discovery.
Clarivate Plc (NYSE: CLVT) has released a report titled Walking the talk on patient centricity, highlighting the importance of personalized patient engagement in life sciences. The report identifies four pillars essential for achieving patient centricity: data inputs, patient involvement, a customer experience approach, and a real-world mindset. It stresses the urgency for life science companies to adapt to this trend for better drug and service outcomes, particularly post-COVID-19. Understanding patient needs is crucial for driving value for both patients and investors.
Clarivate Plc (NYSE: CLVT) released its Biopharma Deals in Review report, showcasing the significant trends in biopharma deal-making for 2021. The report highlights a record 1,968 deals valued at $213.6 billion, with substantial investments in RNA, gene therapies, AI, and oncology. US biotech companies led global capital raising, accounting for 67% of all funds. Notably, oncology deals represented 29% of transactions, with several exceeding $1 billion. This analysis emphasizes the evolving landscape and the growing interest in innovative therapies.
Clarivate Plc (NYSE: CLVT), a global leader in innovation insights, announced its participation in the Bank of America 2022 Information Services Conference. Jerre Stead, Executive Chair and CEO, along with CFO Jonathan Collins, will present on March 17, 2022, at 8:55 AM Eastern Time. A live webcast of the presentation will be accessible via the company's Investor Relations page, with a replay available for 30 days post-event. Clarivate is committed to accelerating innovation and solving complex problems in science and intellectual property.
Clarivate reported strong financial results for Q4 and full year 2021, with revenues of $560.7 million for Q4 (up 23.1%) and $1.88 billion for the year (up 49.7%). Adjusted Net Income soared 20.4% in Q4, reaching $163.2 million, while for the year, it hit $481.7 million, a 66.6% increase. Subscription revenues rose 25.4% in Q4, driven by the ProQuest acquisition. However, the company faced a net loss of $130.4 million in Q4, reflecting a significant increase from the prior year, primarily due to higher interest expenses and warrant adjustments.
Clarivate Plc (NYSE: CLVT) announced it will release its financial results for Q4 and the full year 2021 on March 10, 2022, prior to market opening. The earnings supplement will be available on its investor website at ir.clarivate.com. A conference call and webcast will be held on the same day at 9:00 AM Eastern Time to discuss the results. Investors can join the live audio broadcast by calling specific numbers for the US, Canada, and international participants. A replay will be accessible until March 23, 2022.
Summary not available.
BioWorld, published by Clarivate Plc (NYSE:CLVT), released an in-depth analysis on long COVID-19, affecting over 100 million globally. The report analyzes 40+ studies assessing the syndrome, developed a consensus definition for standardized research, and tracks 41 drugs in development. Despite the biotech industry's focus on COVID-19 treatments, effective therapeutics for long COVID remain scarce, with only three in late-stage trials. The social impact could be significant as researchers continue to explore disease timelines and symptoms across diverse demographics.
FAQ
What is the current stock price of Clarivate Plc (CLVT)?
What is the market cap of Clarivate Plc (CLVT)?
